Acute Exercise and Pancreatic Endocrine Function

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01812590

Enrollment

Registered

2013-03-18

Start date

2013-01-31

Completion date

2013-10-31

Last updated

2014-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Brief summary

Subjects with type 2 diabetes will be stratified into two-quantiles based on ambient hyperglycemia (fasting glucose and HbA1c) and then the effects of a single aerobic exercise bout (1-hour at 50%VO2max) on pancreatic endocrine function will be determined.

Interventions

BEHAVIORALExercise

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

30 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Previous diagnosis with type 2 diabetes, or newly detected in our screening procedures * Age 30-70 years * BMI 20-40 kg/m2

Exclusion criteria

* Treatment with insulin * Contraindication to exercise as determined by ECG * Pregnancy * Active weight loss in the previous 6 months * Actively engaged in exercise training programs * Evidence of chronic pulmonary, cardiovascular, hepatic, renal, or hematological disease

Design outcomes

Primary

Measure	Time frame	Description
Pancreatic endocrine function	24-hours following a period of rest/exercise	Insulin and glucagon secretory responses to intravenous glucose (hyperglycemic clamp 5.4 mmol/l above basal), glucagon-like peptide-1 (0.5 pmol/kg/min), and arginine (5 g injection) will be determined.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026